Dihydromyricetin increases endothelial nitric oxide production and inhibits atherosclerosis through microRNA-21 in apolipoprotein E-deficient mice
Open Access
- 1 May 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (10), 5911-5925
- https://doi.org/10.1111/jcmm.15278
Abstract
Natural products were extracted from traditional Chinese herbal emerging as potential therapeutic drugs for treating cardiovascular diseases. This study examines the role and underlying mechanism of dihydromyricetin (DMY), a natural compound extracted from Ampelopsis grossedentata, in atherosclerosis. DMY treatment significantly inhibits atherosclerotic lesion formation, proinflammatory gene expression and the influx of lesional macrophages and CD4-positive T cells in the vessel wall and hepatic inflammation, whereas increases nitric oxide (NO) production and improves lipid metabolism in apolipoprotein E-deficient (Apoe(-)(/)(-)) mice. Yet, those protective effects are abrogated by using NOS inhibitor L-NAME in Apoe(-)(/)(-) mice received DMY. Mechanistically, DMY decreases microRNA-21 (miR-21) and increases its target gene dimethylarginine dimethylaminohydrolase-1 (DDAH1) expression, an effect that reduces asymmetric aimethlarginine (ADMA) levels, and increases endothelial NO synthase (eNOS) phosphorylation and NO production in cultured HUVECs, vascular endothelium of atherosclerotic lesions and liver. In contrast, systemic delivery of miR-21 in Apoe(-)(/)(-) mice or miR-21 overexpression in cultured HUVECs abrogates those DMY-mediated protective effects. These data demonstrate that endothelial miR-21-inhibited DDAH1-ADMA-eNOS-NO pathway promotes the pathogenesis of atherosclerosis which can be rescued by DMY. Thus, DMY may represent a potential therapeutic adjuvant in atherosclerosis management.Funding Information
- National Natural Science Foundation of China (81400331, 81703818, 81803767)
This publication has 47 references indexed in Scilit:
- 4-HNE Increases Intracellular ADMA Levels in Cultured HUVECs: Evidence for miR-21-Dependent MechanismsPLOS ONE, 2013
- MicroRNA-181b regulates NF-κB–mediated vascular inflammationJCI Insight, 2012
- eNOS Protects from Atherosclerosis Despite Relevant Superoxide Production by the Enzyme in apoE−/− MicePLOS ONE, 2012
- Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncouplingBritish Journal of Pharmacology, 2011
- Role of Asymmetrical Dimethylarginine in Inflammation-Induced Endothelial Dysfunction in Human AtherosclerosisHypertension, 2011
- MicroRNA-21 targets peroxisome proliferators-activated receptor-α in an autoregulatory loop to modulate flow-induced endothelial inflammationProceedings of the National Academy of Sciences of the United States of America, 2011
- Dimethylarginine Dimethylaminohydrolase Overexpression Ameliorates Atherosclerosis in Apolipoprotein E-Deficient Mice by Lowering Asymmetric DimethylarginineThe American Journal of Pathology, 2010
- Role of Dimethylarginine Dimethylaminohydrolases in the Regulation of Endothelial Nitric Oxide ProductionOnline Journal of Public Health Informatics, 2009
- Getting to the site of inflammation: the leukocyte adhesion cascade updatedNature Reviews Immunology, 2007
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseThe New England Journal of Medicine, 2005